hotspot -WSS

hotspot

author：knowledge 2025-09-29 01:06:08 - browse：33

Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty liver disease.

While the study’s primary goal of improving liver fibrosis, or scarring, was not achieved, the Akero drug, called efruxifermin, outperformed placebo by 10 percentage points. The drug also resolved NASH symptoms, including reductions in liver fat and inflammation, and improved other markers of the disease.

“These are the best data reported to date for any NASH drug in this patient population,” said Kitty Yale, Akero’s chief development officer. “We missed the primary endpoint. We understand that, but there’s actually a lot of hope when you look at the totality of the data.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Can sheer will power keep patients alive in their dying hours?

WSS

NIH nominee Bertagnolli will get October confirmation hearing

What STAT readers think about the FDA and patient advocacy

A new House health package & hospitals’ new site

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Listen: Biogen's potential pivot, & Illumina's next chapter

David Ricks of Eli Lilly: best biopharma CEO of 2023

knowledge

hotspot

entertainment

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Humana sues Biden admin over Medicare Advantage audit rule

Anesthesiologist group: stop taking Ozempic before surgery

Three trends to watch in biotech in 2024

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Medical records are filled with copy

Violet CEO on training clinicians to promote more inclusive care

Duchenne breakthrough therapy leaves behind pioneering families

Medicaid rebukes states for mistakenly disenrolling children

hotspot

Snackable artificial intelligence, expert AI, and the pharma industry

A rare thyroid diagnosis led to unexpected, all

ALS advocates say criticism of new drugs misses bigger picture

Virtual care provider acquires bankrupt Pear's prescription apps

Grail spinoff by Illumina should end disastrous merger attempt

Medicare Advantage beneficiaries sue Humana over algorithm use

focus

entertainment

knowledge

explore